Ioulietta Erotokritou-Mulligan
Overview
Explore the profile of Ioulietta Erotokritou-Mulligan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
81
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guha N, Erotokritou-Mulligan I, Bartlett C, Nevitt S, Francis M, Bassett E, et al.
J Clin Endocrinol Metab
. 2014 Mar;
99(6):2259-68.
PMID: 24606087
Context: The GH-2000 and GH-2004 research groups developed a method for detecting GH misuse in athletes based on the measurement of serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP)....
2.
Erotokritou-Mulligan I, Holt R, Sonksen P
Open Access J Sports Med
. 2013 Nov;
2:99-111.
PMID: 24198576
The use of growth hormone (GH) as a performance enhancing substance was first promoted in lay publications, long before scientists fully acknowledged its benefits. It is thought athletes currently use...
3.
Guha N, Erotokritou-Mulligan I, Nevitt S, Francis M, Bartlett C, Cowan D, et al.
Drug Test Anal
. 2013 Nov;
5(11-12):843-9.
PMID: 24173773
Insulin-like growth factor-I (IGF-I) is reportedly misused by elite athletes, either alone or with growth hormone (GH). The GH-2000 and GH-2004 research groups previously developed a method for detecting GH...
4.
Guha N, Erotokritou-Mulligan I, Bartlett C, Cowan D, Bassett E, Stow M, et al.
Drug Test Anal
. 2012 Apr;
4(6):455-9.
PMID: 22511534
A method based on two serum biomarkers - insulin-like growth factor-I (IGF-I) and pro-collagen type III N-terminal propeptide (P-III-NP) - has been devised to detect growth hormone (GH) misuse. The...
5.
Erotokritou-Mulligan I, Guha N, Stow M, Bassett E, Bartlett C, Cowan D, et al.
Growth Horm IGF Res
. 2012 Feb;
22(2):53-8.
PMID: 22305721
Background: The GH-2000 project developed a method for detecting GH misuse based on the measurement of insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). The...
6.
Holt R, Erotokritou-Mulligan I, McHugh C, Bassett E, Bartlett C, Fityan A, et al.
Eur J Endocrinol
. 2010 Apr;
163(1):45-54.
PMID: 20421332
Context: The GH-2000 team proposed a method based on IGF1 and type III pro-collagen (P-III-P) to detect exogenously administered GH. As previous studies involved predominantly white European athletes, it is...
7.
Guha N, Erotokritou-Mulligan I, Burford C, Strobridge G, Brigg J, Drake T, et al.
J Clin Endocrinol Metab
. 2010 Apr;
95(6):2969-76.
PMID: 20410221
Context: A method based on two GH-dependent markers, IGF-I and pro-collagen type III N-terminal peptide (P-III-P), has been devised to detect exogenously administered GH. Because previous studies on the detection...
8.
Erotokritou-Mulligan I, Holt R
Endocrinol Metab Clin North Am
. 2010 Feb;
39(1):33-43, viii.
PMID: 20122448
It is believed that insulin and insulin-like growth factor I (IGF-I) are abused by professional athletes, either alone or in combination with growth hormone (GH) and anabolic steroids. The recent...
9.
Erotokritou-Mulligan I, Bassett E, Cowan D, Bartlett C, Milward P, Sartorio A, et al.
Clin Endocrinol (Oxf)
. 2009 Aug;
72(4):520-6.
PMID: 19650783
Background: Growth Hormone is abused by athletes for its lipolytic and anabolic properties. Its use is prohibited by the World Anti-Doping Agency. The GH-2000 project developed a methodology to detect...
10.
Bassett E, Erotokritou-Mulligan I
Growth Horm IGF Res
. 2009 Jun;
19(4):361-5.
PMID: 19515593
The detection of growth hormone (GH) abuse by athletes raises statistical problems as well as biochemical ones. We outline the statistical approaches to the various issues which have arisen during...